GRAIL, Inc. (NASDAQ:GRAL) Given Average Rating of “Hold” by Brokerages

Shares of GRAIL, Inc. (NASDAQ:GRAL) have earned an average recommendation of “Hold” from the ten ratings firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $67.00.

Several brokerages recently weighed in on GRAL. Guggenheim lowered their price objective on GRAIL from $130.00 to $75.00 and set a “buy” rating for the company in a report on Monday, March 30th. TD Cowen lifted their target price on GRAIL from $65.00 to $69.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Wolfe Research began coverage on GRAIL in a research note on Tuesday, June 2nd. They issued a “peer perform” rating for the company. Wall Street Zen upgraded GRAIL from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Robert W. Baird set a $70.00 target price on GRAIL in a research note on Wednesday, May 6th.

More GRAIL News

Here are the key news stories impacting GRAIL this week:

• Neutral Sentiment: Multiple law firms, including Rosen, Pomerantz, Schall, Glancy Prongay, and others, issued reminders that investors who bought GRAL between May 13, 2025 and February 19, 2026 may join the securities fraud class action, with an August 4, 2026 lead-plaintiff deadline. Article Title
• Neutral Sentiment: The lawsuits allege GRAIL misled investors about its NHS-Galleri trial results, and one filing says the February 20 trial update erased more than $2.2 billion in market value, underscoring the magnitude of the alleged disclosure issue. Article Title
• Negative Sentiment: The mounting legal announcements add to investor uncertainty and could weigh on sentiment toward GRAIL as shareholders await further developments in the class action process. Article Title

GRAIL Stock Down 1.6%

Shares of GRAIL stock opened at $61.11 on Wednesday. The firm has a market cap of $2.62 billion, a P/E ratio of -5.89 and a beta of 3.15. GRAIL has a fifty-two week low of $29.95 and a fifty-two week high of $118.84. The business has a 50-day moving average price of $59.70 and a 200 day moving average price of $72.14.

GRAIL (NASDAQ:GRAL) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($2.29) earnings per share for the quarter, beating the consensus estimate of ($2.76) by $0.47. The firm had revenue of $40.79 million during the quarter, compared to analyst estimates of $39.16 million. GRAIL had a negative return on equity of 16.42% and a negative net margin of 253.22%. As a group, equities research analysts anticipate that GRAIL will post -10.91 earnings per share for the current year.

Insider Buying and Selling

In other GRAIL news, President Joshua J. Ofman sold 61,665 shares of GRAIL stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $49.92, for a total value of $3,078,316.80. Following the completion of the transaction, the president directly owned 371,216 shares in the company, valued at $18,531,102.72. The trade was a 14.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Aaron Freidin sold 45,806 shares of GRAIL stock in a transaction that occurred on Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total value of $2,286,635.52. Following the completion of the transaction, the chief financial officer owned 260,669 shares of the company’s stock, valued at approximately $13,012,596.48. The trade was a 14.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 232,464 shares of company stock valued at $11,621,242. 1.83% of the stock is currently owned by insiders.

Hedge Funds Weigh In On GRAIL

Several hedge funds and other institutional investors have recently made changes to their positions in GRAL. Farallon Capital Management LLC boosted its position in shares of GRAIL by 73.7% during the fourth quarter. Farallon Capital Management LLC now owns 2,342,684 shares of the company’s stock worth $200,510,000 after buying an additional 993,684 shares during the period. Morgan Stanley boosted its position in shares of GRAIL by 63.8% during the fourth quarter. Morgan Stanley now owns 1,511,687 shares of the company’s stock worth $129,385,000 after buying an additional 588,647 shares during the period. State Street Corp boosted its position in shares of GRAIL by 38.8% during the fourth quarter. State Street Corp now owns 1,827,523 shares of the company’s stock worth $156,418,000 after buying an additional 510,546 shares during the period. Baker BROS. Advisors LP boosted its position in shares of GRAIL by 27.9% during the fourth quarter. Baker BROS. Advisors LP now owns 2,085,333 shares of the company’s stock worth $178,484,000 after buying an additional 455,208 shares during the period. Finally, Alyeska Investment Group L.P. acquired a new position in shares of GRAIL during the fourth quarter worth approximately $37,874,000.

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.